Search company, investor...

Novacta Biosystems

novactabio.com

Founded Year

2003

Stage

Unattributed | Alive

Total Raised

$7.7M

Last Raised

$7.7M | 14 yrs ago

About Novacta Biosystems

Aiming to leverage the knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.

Headquarters Location

Broadwater Road BioPark Hertfordshire

AL7 3AX,

United Kingdom

(+44017) 073-561-3044

Missing: Novacta Biosystems's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Novacta Biosystems's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Novacta Biosystems

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Novacta Biosystems is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Novacta Biosystems Patents

Novacta Biosystems has filed 9 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/9/2011

11/24/2015

Engine technology, Sugar substitutes, Engine components, Engine fuel system technology, Fuel injection systems

Grant

Application Date

8/9/2011

Grant Date

11/24/2015

Title

Related Topics

Engine technology, Sugar substitutes, Engine components, Engine fuel system technology, Fuel injection systems

Status

Grant

Latest Novacta Biosystems News

Novacta Biosystems Limited Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Dec 6, 2016

Novacta Biosystems Limited Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 11:57 EST 6 Dec 2016 | BioPortfolio Reports Home » Topics » Biotechnology Business » Latest News » Novacta Biosystems Limited Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Novacta Biosystems Limited Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Novacta Biosystems Limited since January 2007. Key Findings Provides intelligence on Novacta Biosystems Limited MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Novacta Biosystems Limited and its subsidiaries since 2007. Information about key financial and legal advisors for Novacta Biosystems Limited's financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Novacta Biosystems Limited's growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

Novacta Biosystems Frequently Asked Questions (FAQ)

  • When was Novacta Biosystems founded?

    Novacta Biosystems was founded in 2003.

  • What is Novacta Biosystems's latest funding round?

    Novacta Biosystems's latest funding round is Unattributed.

  • How much did Novacta Biosystems raise?

    Novacta Biosystems raised a total of $7.7M.

  • Who are the investors of Novacta Biosystems?

    Investors of Novacta Biosystems include Celtic Pharma, Westgate Hall, Midven, IQ Capital, Esperante and 8 more.

  • Who are Novacta Biosystems's competitors?

    Competitors of Novacta Biosystems include Cognate BioServices, HumanZyme, Cellular Dynamics International, Life Technologies Corporation, BAC and 12 more.

Compare Novacta Biosystems to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

C
Core Dynamics

Core Dynamics is a development-stage company focused on the freezing and lyophilization of white blood cells and stem cells and their preservation and storage at room temperature.

Kiyatec Logo
Kiyatec

Kiyatec specializes in modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision-making and drive drug development. Its predictive clinical tests provide oncologists with patient-specific response profiles to the current standard of care drugs prior to treatment selection. The company was founded in 2005 and is based in Greenville, South Carolina.

F
Functional Biosciences

Functional Biosciences specializes in genomics research. The company produces reagents and an informatics tools, and aims to provide services that simplify preclinical drug development, reduce the costs of toxicity screening, improve the efficiency of DNA sequencing, and more.

N
Neucel Specialty Cellulose

Neucel is an aggressive new player in the global market for specialty cellulose products. The company aim to set the "˜gold standard' in the production of dissolving cellulose.

B
Bionas

Bionas specializes in analyzing systems for in vitro profiling the metabolic activity of cells with special respect to cellular bioenergetics, adhesion and morphology.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.